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Abstract: Approximately 30 to 40% of patients with advanced lung
cancer will develop bone metastases in the course of their disease,
resulting in a significant negative impact on both morbidity and
survival. Skeletal complications of bone metastases include pain,
pathologic fractures, spinal cord compression, and hypercalcemia.
Total medical care costs are greater among patients with bone
metastases who develop skeletal complications. A randomized phase
III trial of the third generation bisphosphonate zoledronic acid has
shown clinical benefit in the management of a subgroup of patients
with bone metastases from lung cancer. Zoledronic acid treatment
was associated with a reduction in both the risk of, and time to, a
skeletal-related event. One of the markers of bone resorption,
N-telopeptide, is both prognositic for development of skeletal-
related events and predictive for benefit from zoledronic acid. In
preclinical models, bisphosphonates have also demonstrated antitu-
mor activity and are therefore currently being evaluated in adjuvant
trials. Inhibition of the receptor activator of nuclear factor kappa B
ligand-RANK pathway can reduce osteoclast-mediated bone resorp-
tion, and trials comparing receptor activator of nuclear factor kappa
B ligand inhibitors with bisphosphonates are ongoing, including
patients with lung cancer. In this article, we review the management
of bone metastases and hypercalcemia as well as potential future
directions for bone directed therapies in patients with lung cancer.
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The incidence of bone metastases in advanced lung cancerpatients is estimated to range from 30 to 40%.1,2 Further-
more, at autopsy, lung was the primary site in more than 50%
of cases in patients who presented with bone metastases and
an occult primary.3 In non-small cell lung cancer (NSCLC) in
particular, a recent single-institution retrospective review of
435 patients with NSCLC revealed an incidence of 24% for
skeletal metastases with the majority of those (66%) detected
at the time of initial staging.4 The axial skeleton and proximal
long bones were the most commonly involved and approxi-
mately half of these patients required radiation therapy.
Bone metastases are seldom asymptomatic, and in 2.3%
of lung cancer patients, symptoms of bone metastases are the
first manifestation of malignancy.5 In fact the most frequent
form of pain reported in cancer patients is pain from skeletal
metastases and 80% of lung cancer patients with bone me-
tastases may suffer from bone pain either at presentation or
some time during the course of their cancer.4,6 Bone metas-
tases frequently lead to skeletal morbidity that can result in a
significant negative impact on both quality of life and sur-
vival; the median survival for patient with bone metastases is
6 months.1
Skeletal-related events (SREs) is a term used to de-
scribe a collection of adverse events associated with bone
metastases that are collated to use as an end point in clinical
trials. SREs include pathologic fractures, the requirement for
surgery or radiotherapy, spinal cord and nerve root compres-
sion, and hypercalcemia of malignancy.1 Patients who expe-
rience an initial SRE are at high risk for subsequent SREs.7
These SREs result in impaired mobility, reduced quality of
life, and frequently require therapeutic intervention (radiation
therapy, surgery, and systemic treatments) that may add
considerable cost to the end of life care. Indeed, a retrospec-
tive review from Japan reported a 30% incidence of skeletal
metastases in patients with NSCLC, half of whom subse-
quently experienced an SRE.8
Mechanisms of Bone Metastases Development
and Bone Destruction
Neoplastic involvement in the bone arises from dys-
regulation of the normal bone remodeling process, usually
tightly controlled in balance between the bone resorption
function of osteoclasts and the remodeling and bone forma-
tion mediated by osteoblasts.9 The “vicious cycle” of bone
metastases occurs when tumor cells stimulate osteoclast ac-
tivity leading to bone resorption. The bone matrix then
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releases cytokines that stimulate further tumor growth, hence
creating a self-propagating circuit of tumor growth and bone
destruction (Figure 1).
More specifically, tumor production of cytokines such
as parathyroid-hormone-related peptide (PTHrP) and inter-
leukin 8 stimulates osteolysis.10–12 This mechanism works
through the RANKL (receptor activator of nuclear factor kappa
B ligand)/receptor activator of nuclear factor kappa (RANK)/
OPG (osteoprotegerin) axis. RANKL, also known as osteop-
rotogerin ligand or tumor necrosis factor-related activation-
induced cytokine, has been identified as a key mediator of
osteoclast differentiation, function and survival.13–15 RANKL
is expressed on osteoblasts, both in transmembrane and
soluble form, and when increased expression is stimulated by
factors such as PTHrP or prostaglandins, RANKL binds to
RANK receptors on osteoclast precursors, which in turn
stimulates migration of cancer cells to the “fertile soil” of
bone.16 Maturation of osteoclast precursors to multinucleated
osteoclasts and finally to activated osteoclasts is initiated on
RANKL/RANK binding. Osteoclast-mediated bone resorp-
tion in turn causes release of growth factors, such as trans-
forming growth factor-beta and insulin-like growth factor 1,
that complete the cycle by stimulating further tumor
growth.17–19 RANKL is regulated by OPG, a member of the
tumor necrosis factor receptor family that is normally present
in bone marrow. OPG acts by binding to and inhibiting
RANKL, thereby preventing the RANKL-RANK binding
that stimulates osteoclast differentiation and maturation.20 It
is disruption of this RANK/RANKL/OPG axis that is key to
progression of bone metastases.16,21
Although the overwhelming majority of lung cancer
bone metastases are osteolytic in nature, case reports exist of
osteoblastic bone metastases. Limited clinical evidence hy-
pothesizes that these may have different etiology, and possi-
bly are more common in patients with mutations of the
epidermal growth factor receptor.22
In addition, in preclinical models, adhesion of cancer
cells to the bone microenvironment have been shown to
increase production of angiogenic factors (such as vascular
endothelial growth factor) that enhance tumor growth in
bone.23 Clinical correlates of this mechanism have not yet
been demonstrated in lung cancer. However, expression of
bone sialoprotein in lung cancers, not usually seen in normal
lung tissue, is strongly correlated with subsequent develop-
ment of bone metastases and also seems to be an independent
adverse prognostic factor.24,25 This may be a useful potential
target for future drug development. Finally, preclinical mouse
models also have demonstrated up-regulation of the PTHrP
and the ezrin genes in lung cancer bone metastases, poten-
tially mediated by transforming growth factor-beta. Ezrin
may be a potential target for future research.26
Economic Impact of Skeletal Complications
In a retrospective observational study using a large
American health insurance claims database, Delea et al.27
reported the high cost of treating SREs in lung cancer. SREs
were defined as pathologic fractures, cord compression, hy-
percalcemia, bone surgery, radiotherapy, or initiation of opi-
oid analgesic therapy (although initiation of opiates is not
normally considered an SRE). Charges were compiled for
out-patient procedures, hospital stays, doctor office visits,
prescriptions, and home and long-term care. Patients with
SREs were matched to similar patients without SREs by age
and comorbidity scores using a propensity score approach. Of
FIGURE 1. The vicious cycle of
bone destruction and tumor prolif-
eration.
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534 patients identified with lung cancer and bone metastases,
295 (55%) experienced one or more SREs over a mean
follow-up of 5.6 months, whereas 25% of patients had two or
more SREs. After matching, there were 162 patients each in
the SRE and non-SRE groups. Costs of treatment of SREs
were estimated to be approximately $9500. Total medical
care costs were almost $28,000 in patients with SREs and
were significantly higher that in patients without SREs (p 
0.001). Radiation therapy accounted for 55% of the treatment
cost (compared with 25% for bone surgery), and 54% of costs
were due to in-patient hospitalization. The authors concluded
that the costs of SREs in patients with lung cancer and bone
metastases were substantial and potentially greater than pre-
viously estimated, thereby providing a rationale for treatment
to prevent SREs.
Provisional data from the United Kingdom suggests
that the use of zoledronic acid in lung cancer patients with
bone metastases may be cost effective, with the mean drug
cost (£1473) slightly lower than the cost of additional SREs
(£1562) seen in an untreated population. However, this anal-
ysis was highly modeled and fully published details are not
yet available.28
MANAGEMENT OF BONE METASTASES
Treatment of pain is one of the most important aspects
in the management of bone metastases. Nonsteroidal antiin-
flammatory drugs can be used alone for mild pain from bone
metastases and in conjunction with narcotic analgesics for
more severe pain. Corticosteroids, tricyclic antidepressants,
anticonvulsants, and neuroleptics have been all used in con-
junction with opioids for improved pain control.29
Radiation therapy is the most common treatment for
palliation of painful bone metastases, stabilization of impend-
ing pathologic fractures, and treatment or prevention of spinal
cord compression. In a review of palliative therapy for lung
cancer, Bezjak30 observed that the dose fractionation used for
the treatment of bone metastases varies widely from single
fractions, usually in doses of 8 Gy, to short-course radiation
of 20 to 30 Gy in 8 to 10 fractions, and even more radical
treatment of up to 50 Gy. Reported pain relief response rates
ranged from 65 to 100%, although the response criteria used
in the studies varied widely. A recent guideline from the
Supportive Care Guidelines Group of Cancer Care Ontario
recommended the following: “Where the treatment objective
is pain relief, a single 8 Gy treatment, prescribed to the
appropriate target volume, is recommended as the standard
dose-fractionation schedule for the treatment of symptomatic
and uncomplicated bone metastases.”31 This guideline is
supported by the results of two meta-analyses of radiotherapy
dose-fractionation trials that found no relation with either
dose or fractionation scheme in the palliation of bone metas-
tases in multiple tumor types including lung cancer.32,33
Interestingly, however, the former meta-analysis showed that
the need for retreatment was significantly higher in patients
treated with only a single fraction (p  0.002).32 Clearly, not
all patients are suitable for single fraction therapy.
A recent review of the factors influencing the use of
single versus multiple fractions of radiotherapy for bone
metastases at the Princess Margaret Hospital, Toronto
showed that out of 882 courses of radiation, only 283 (32%)
were delivered as a single fraction.34 Patients given single
fractions tended to be older, to have a history of weight loss,
and to be of poorer performance status. The study included
358 patients with lung cancer, but there was no difference in
selection of dose or fractionation by tumor type. These
clinical factors, particularly short-life expectancy and poor
performance status, may guide clinicians toward treatment
with a single fraction if it is felt that the need for retreatment
would be unlikely.
Surgical intervention is a mainstay of treatment for
pathologic fractures and prevention of impending fractures
when long weight-bearing bones are involved.35 Surgery is
considered in spinal cord compression but is usually limited
to cases where there is spinal instability, failure of conserva-
tive management, progressive neurologic deterioration from
bony collapse, or intractable pain.36,37 Although very uncom-
mon, there are a few case reports that have showed long-term
survival in patients with lung cancer and solitary bone me-
tastases treated with aggressive surgical resection of the both
primary and metastatic sites of disease.38,39
Bisphosphonates for Bone Metastases
Bisphosphonates are a group of compounds that are
stable analogues of naturally occurring inorganic pyrophos-
phate. When bound to hydroxyapatite, they are specific in-
hibitors of osteoclast activity and this subsequently leads to
inhibition of bone resorption.40–42 The most commonly in-
vestigated bisphosphonates in cancer are the first-generation
compound clodronate (Bonefos; Schering AG, Berlin, Ger-
many), second-generation pamidronate (Aredia; Novartis
Pharmaceuticals Corporation, East Hanover, NJ), third-gen-
eration zoledronic acid (Zometa; Novartis Pharma Stein AG,
Stein, Switzerland), and third-generation ibandronate (Boniva;
Roche Laboratories Inc., Nutley, NJ).
In addition to the effect on osteoclasts, in a preclinical
model Reinholz et al.43 demonstrated that the bisphospho-
nates pamidronate and zoledronate decreased osteoblast pro-
liferation and stimulated their differentiation and bone-form-
ing activity. In addition, bisphosphonates have direct effects
on cancer cells by inhibiting tumor cell invasion and adhesion
to bone matrix, and in human breast cancer and prostate
cancer cell lines they have been shown to inhibit growth and
induce apoptosis.44–46
Bisphosphonates are effective therapy for the hypercal-
cemia of malignancy, relief of malignant bone pain and delay
of the onset of progressive bone disease. The majority of
studies evaluating the use of bisphosphonates have been in
bone metastases from breast cancer, multiple myeloma, and
prostate cancer. Phase III trials, comparing pamidronate ver-
sus placebo in breast cancer patients with bone metastases,
demonstrated a significant reduction in the number of SREs,
time to first SRE, pain scores, and use of analgesia for those
receiving pamidronate.47,48 Similar benefits were seen in
multiple myeloma, with a reduction in SREs seen after nine
cycles of pamidronate compared with placebo,49 an effect that
was maintained with long term use up to 21 cycles of
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pamidronate.50 Zoledronic acid, a highly potent third-gener-
ation nitrogen containing bisphosphonate, has shown similar
efficacy to pamidronate in phase III trials for patients with
both breast cancer and multiple myeloma.51,52 Zoledronic acid
is administered as a 15-minute intravenous infusion when com-
pared with a 90-minute infusion for pamidronate. In patients
with metastatic breast cancer, it has been favored over pam-
idronate in a multiple-event analysis. Here, zoledronic acid
was found to further reduce the risk of an SRE and benefits
were maintained over a long follow-up period, in addition to
the convenience of a shorter infusion time.53
In prostate cancer, where bone metastases are predom-
inantly osteoblastic, pamidronate has not been shown to
reduce bone pain or the rate of SREs when compared with
placebo.54 In contrast, zoledronic acid did significantly re-
duce the rate of SREs in metastatic prostate cancer when
compared with placebo.55 Zoledronic acid has therefore dem-
onstrated efficacy in both osteolytic and osteoblastic bone
disease.56
The most common adverse events associated with
bisphosphonate administration include bone pain, fever, ane-
mia, and gastrointestinal disturbances. All bisphosphonates
should be used with caution in patients with risk factors for
renal dysfunction. Rarer side effects such as osteonecrosis of
the jaw have gained considerable attention in breast cancer
and myeloma management, although only isolated cases have
been reported in lung cancer.57
Bisphosphonates have also demonstrated antitumor ac-
tivity based on preclinical evidence in both in vitro and in
vivo studies, including in lung cancer cell lines.58,59 Recently,
in a large phase III trial of adjuvant hormonal therapy in early
stage breast cancer, patients were randomized to receive
zoledronic acid or not. Provisional results have shown a
significant reduction in the risk of disease free survival events
(hazard ratio HR  0.64 0.46, 0.91; p  0.01) and a trend
toward improvement in overall survival (HR  0.60 0.32,
1.11; p 0.10), favoring zoledronic acid.60 Based on these
observations, there may also be a rationale for further trials
in patients with early and advanced stage lung cancer, for
prevention of bone metastases and a possible survival
advantage.
Bisphosphonates for Bone Metastases from Lung
Cancer
Rosen et al.61 conducted a multicenter phase III, dou-
ble-blind, randomized clinical trial comparing zoledronic
acid and placebo in 773 patients with bone metastases from
lung cancer and solid tumors other than breast and prostate
cancer. Patients were randomized to receive zoledronic acid
(4 mg or 8 mg) or placebo every 3 weeks for 9 months, and
patients were then given the option to continue blinded
treatment for a total of 21 months. Because of concerns
regarding renal safety at the higher dose, a protocol amend-
ment led to the 8-mg dose being reduced to 4 mg. Most of the
patients in this group had already completed therapy, but 25%
had their treatment reduced to the lower dose. All patients
received calcium and vitamin D supplements. The primary
end point was the proportion of patients with 1 SREs at 9
or 21 months. Secondary end points were the time to first
SRE, annual incidence of SREs, multiple-event analysis,
pain/analgesic scores, bone lesion response, time to progres-
sion of the disease, and safety (including survival). Hyper-
calcemia was included as secondary efficacy analysis for the
definition of SREs.
Of the 773 patients, 378 had NSCLC and 58 had small
cell lung cancer. Twenty-five percent of patients completed
the 9-month core and 101 patients elected to continue in the
extension phase of study. Compared with placebo, treatment
with 4 mg of zoledronic acid resulted in a nonsignificant
reduction in the proportion of patients with an SRE (38 versus
44%; p  0.127). However, when hypercalcemia was in-
cluded in analysis of skeletal events, zoledronic acid signif-
icantly reduced the proportion of patients with an SRE (38
versus 47%; p  0.039) (Table 1). Zoledronic acid signifi-
cantly extended the median time for the development of SRE
(including hypercalcemia) by almost 3 months (230 days
versus 155 days; p  0.007) and the time to first pathologic
fracture (238 days versus 161 days; p 0.031). Furthermore,
in multiple-event analysis a 27% reduction in the risk of
developing an SRE (including hypercalcemia) was observed
(HR  0.70, p  0.006), a finding that was similar in the
subset containing only lung cancer patients (HR  0.71, p 
0.036).
TABLE 1. Comparison of Zoledronic Acid 4 mg vs. Placebo
in Solid Tumors
Zoledronic
Acid (4 mg) Placebo p
Overall number of patients 257 250
Lung cancer patients 141 139
Skeletal-related event outcomes for all
patients
Proportion with one SRE within 9 mo 38% 44% 0.13
Any skeletal-related event (including
hypercalcemia)
38% 47% 0.04
Radiation to bone 27% 32%
Pathological fracture 16% 21%
Spinal cord compression 3% 4%
Hypercalcemia 0% 3% 0.004
Time to first SRE (including HCM) 230 d 155 d 0.01
Time to first pathological fracture 238 d 161 d 0.03
Skeletal-related event outcomes for
NSCLC patients
Proportion with one SRE within 9 mo 42% 45% 0.56
Time to first SRE 171 d 151 d 0.19
Hazard ratio of occurrence of SREs in
lung cancer patients (NSCLC 
SCLC)
SRE (not including hypercalcemia) 0.73 1 0.61
SRE (including hypercalcemia) 0.71 1 0.04
Survival outcomes for all patients
Median time to disease progression 89 d 84 d 0.12
Median overall survival 203 d 183 d 0.62
Data from Rosen et al.61
SRE, skeletal-related event; HCM, hypercalcemia of malignancy; NSCLC, non-
small cell lung cancers; SCLC, small cell lung cancers.
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Biochemical markers of bone resorption (N-telopeptide
NTX and deoxypyridinoline) decreased significantly from
baseline with zoledronic acid, 4 mg. There was no significant
difference in survival and global quality of life parameters
between the groups. Zoledronic acid at a dose of 4 mg was
found to be safe and well tolerated, with the most common
reported adverse events being bone pain, nausea, anemia, and
emesis. Renal impairment was higher in the zoledronic acid
group when this was administered as a 5-minute infusion, but
after a protocol amendment changed the infusion time to 15
minutes there was no significant difference in renal impair-
ment between treatment and placebo groups.
The authors subsequently reported a long-term fol-
low-up of the same cohort of patients.62 At 21 months, the
main study findings were confirmed, where patients treated in
the 4 mg cohort had a 31% reduction in the risk of skeletal
complications compared with placebo (HR  0.69, 95%
confidence interval 0.54–0.89, p  0.003). However, the
primary end point, the number of patients with an SRE at 21
months, still did not reach statistical significance (39 versus
46%, p  0.127). In view of the poor prognosis for this
patient population, who had a median survival of 6 months,
only a minority of patients completed the study (approxi-
mately 25%). However, this was the first trial to show clinical
benefit of bisphosphonate therapy in patients with bone me-
tastases associated with solid tumors other than breast and
prostate cancer.
More recently a retrospective analysis, of only the
NSCLC patients from this study, correlated high-baseline
levels of NTX with an increased risk of SREs in both the
zoledronic acid and placebo groups. Among 144 patients with
a high-baseline NTX, treatment with zoledronic acid signif-
icantly reduced the risk of death (HR  0.65, p  0.025), in
addition to a reduction in SREs seen across all patients
(relative risk 0.62, p  0.001).63 A further analysis of the
same subgroup of patients investigated the influence of bone-
specific alkaline phosphatase (BALP). Although zoledronic
acid was not predictive of improved survival in patients with
elevated baseline BALP, in patients with both elevated NTX
and elevated BALP treatment with zoledronic acid was as-
sociated with a 46% reduction in risk of death (p  0.006)
when compared with placebo64 (Table 2).
Although we are not aware of other randomized studies
of zoledronic acid in lung cancer yet reported, there is more
evidence to support its use. In a retrospective analysis of a US
claims database, zoledronic-acid-treated lung cancer patients
with bone metastases had a 30 to 40% reduced risk of skeletal
complications when compared with untreated patients.65
There are no randomized trials of other bisphosphonates in
the treatment of skeletal complication from solid tumors other
than breast or prostate cancer. In a single arm phase II study,
pamidronate was administered to 20 patients (16 NSCLC and
4 small cell lung cancer) with bone pain because of lung
cancer metastases.66 Pain relief was achieved in 12 patients
(60%) and normalization of serum calcium was seen in all
nine patients with hypercalcemia.
Ibandronate is a third-generation bisphosphonate that is
available in both intravenous and oral formulations. In a
feasibility study, 4 mg ibandronate was safely infused over 20
minutes in 32 patients with bone metastases. There was a
significant decrease in serum calcium levels (p  0.03) and
24 patients stabilized or reduced their need for analgesic
treatment.67 Ibandronate has been compared with pamidr-
onate in patients with bone metastases from breast or lung
cancer.68 Although this study only included 25 patients (10
with lung cancer), the authors concluded that ibandronate
seemed superior to pamidronate in alleviating pain, improv-
ing motility, improving overall quality of life, and reducing
bone resorption in patients with bone metastases from these
two malignancies. A Chinese phase IV trial (NCT00492843)
has recently been terminated because of poor accrual. It was
aiming to assess the efficacy and safety of a loading dose
versus standard dose of intravenous ibandronate in reducing
pain in patients with lung cancer and bone metastases. This is
based on several open-label trials that suggest that intrave-
nous ibandronate administered on consecutive days can pro-
vide rapid relief from severe or opioid-resistant metastatic
bone pain of various primary tumors.69,70
TABLE 2. Biomarkers in a NSCLC Patient Subset of a Study of Zoledronic Acid 4 mg
vs. Placebo in Solid Tumors, Demonstrating Elevated NTX is Prognostic for SREs and
Predictive of Benefit from Zoledronic Acid
Zoledronic Acid Placebo p
N-telopeptide
Number of patients with high-baseline NTX 102/183 (56%) 42/80 (53%)
Relative risk of SRE if high-baseline NTX
(reference to normal baseline NTX)
1.81 1.64
p  0.01 p  0.07
Relative risk of death (95% CI) if normal baseline NTX 1.33 (0.84–2.09) 1 0.22
Relative risk of death (95% CI) if high-baseline NTX 0.65 (0.45–0.95) 1 0.025
NTX and bone-specific alkaline phosphatase
Relative risk of death if high-baseline BALP Not stated 1 0.40
Relative risk of death if high-baseline BALP and high NTX 0.54 1 0.006
Relative risk of death if low-baseline BALP and high NTX NS
Data from Hirsh et al.63 and Brown et al.64
SRE, skeletal-related event; NTX, N-telopeptide; BALP, bone specific alkaline phosphatase.
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Finally, in a retrospective study evaluating 94 patients
who received radiation for bone metastases from either breast
cancer or NSCLC, 27 patients (12 with NSCLC) also re-
ceived clodronate, an oral bisphosphonate. Pain measures
(increase in pain on the first day of radiation and complete
pain relief after radiation) were better in the group that
received clodronate compared with those treated with radio-
therapy alone.71
For the future, a phase III trial in Europe is currently
evaluating the safety and efficacy of zoledronic acid in the
prevention or delaying of bone metastases in patients with stage
IIIA and IIIB NSCLC. This trial is open and actively recruiting
participants (clinicaltrials.gov identifier NCT00172042). The
US75 trial (Z-PACT, NCT00086268) is an open label, multi-
center phase III study evaluating the effect of zoledronic acid in
combination with chemotherapy (carboplatin and docetaxel)
in patients with stage IIIB/IV NSCLC not metastatic to bone.
This study has completed accrual and results are awaited. A
phase II study of zoledronic acid in lung cancer patients with
bone metastases is currently recruiting, with the primary
outcome measure being change in tartrate resistant acid
phosphatase—5b levels. This study will help to define the
role of markers of bone resorption in this group of patients
(NCT00265200).
Targeting RANK Ligand
Denosumab (AMG142, Amgen Inc., Thousand Oaks,
CA), a fully humanized monoclonal antibody with high
affinity and specificity for RANKL, can bind and neutralize
the activity of human RANKL. This action, that is similar to
the action of native OPG, has been shown to result in
inhibition of osteoclast function and bone resorption.72 A
phase II study in 255 women with breast cancer-related bone
metastases evaluated five different doses of subcutaneously
administered denosumab and one cohort treated with intra-
venous bisphosphonates (91% received zoledronic acid). All
five denosumab arms showed marked biologic activity in
suppressing bone turnover and reducing SREs, which was
similar to bisphosphonate arm.73 In the above study and
others, denosumab has been generally well tolerated; the
most common adverse events reported were fatigue, nau-
sea, headache, bone pain, and upper respiratory tract in-
fection. Larger phase III trials are underway to investigate
the effect of denosumab compared with zoledronic acid for
prevention and treatment of complications caused by bone
metastases in patients with advanced cancer (including
lung cancer). The selected dose was 120 mg subcutane-
ously every 4 weeks based on favorable efficacy, safety,
and pharmacokinetic profile.
MANAGEMENT OF HYPERCALCEMIA
Hypercalcemia of malignancy is a fairly common and
life-threatening skeletal complication of bone metastases as-
sociated with lung cancer. A prospective study in the 1970s
of 200 patients with lung cancer showed a 12.5% incidence of
hypercalcemia.74 Squamous cell carcinoma is the most com-
mon histology associated with this presentation, generally in
advanced-stage disease,75 although hypercalcemia is occa-
sionally reported in small cell lung cancer as well.76 Although
hypercalcemia may occur with osteolytic bone metastases, it
is often seen in the absence of osseous involvement because
of humoral and cytokine factors such as PTHrP, interleu-
kin-1, transforming growth factor alpha, tumor necrosis fac-
tor, prostaglandin, and lymphotoxin.77 PTHrP stimulates
bone resorption and renal phosphate wasting by working
through a common receptor for PTHrP and parathyroid hor-
mone, resulting in hypercalcemia and hypophosphatemia.
PTHrP frequently can be detected in the serum of patients
with humoral hypercalcemia of malignancy.78
Clinical symptoms of hypercalcemia depend on the
serum calcium level and the rate of rise. Early symptoms
include nausea and vomiting, fatigue, anorexia, muscle weak-
ness, constipation, polyuria, nocturia, and polydypsia. If un-
treated patients can become severely dehydrated and subse-
quently develop renal impairment. Further effects include
confusion, psychosis, seizure, coma, arrhythmia, pruritis, and
ileus. The goals of treatment include vigorous rehydration,
inhibition of bone resorption and/or promotion of calcium
excretion, and treatment of the underlying malignancy.79
The bisphosphonates are the most commonly used
drugs used in the management of the hypercalcemia of
malignancy, including lung cancer. In a pooled analysis of
two randomized trials comparing zoledronic acid with pam-
idronate for patients with hypercalcemia, a higher complete
response rate was seen in those treated with 4 mg zoledronic
acid (88 versus 70%, p  0.002).80 As discussed earlier, in
the study by Rosen et al.61 (zoledronic acid versus placebo in
lung cancer and other solid tumor patients with bone metas-
tases) hypercalcemia was completely prevented in the 4 mg
zoledronic acid arm.
FUTURE DIRECTIONS
All studies of treatment for bone metastases have used
different end points to assess response, including degree of
pain relief, need for narcotic analgesics, development of
hypercalcemia and development of pathologic fractures to
name but a few. Furthermore, timing of these assessments has
varied from study to study from 1 month to almost 2 years.
Clearly a 2-year end point would be of little relevance in
advanced lung cancer patients, whereas it might be totally
appropriate in prostate and breast cancer patients. Chow et
al.81 have published an international consensus statement
that recommends a uniform set of criteria for the selection
of outcome measures and the timing of assessments in
radiotherapy trials for bone metastases. Many of the rec-
ommendations may also be applicable to medical trials for
bone metastases. In addition, the European Organization
for the Research and Treatment of Cancer is developing a
bone metastasis quality of life module that may also help
to standardize symptomatic response to therapy and eval-
uate the quality of life effects that bone metastases have on
cancer patients.82
Another limitation to clinical research strategies to
evaluate therapies for bone metastases are the limitations of
current radiologic techniques.83 There has, therefore, been
significant impetus to develop biochemical surrogates of bone
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function. Biochemical markers of bone metabolism are asso-
ciated with both the formation and destruction of bone. Bone
resorption markers include NTX, tartrate resistant acid phos-
phatase—5b, pyridinoline, and deoxypyridinoline, whereas
BALP is a bone formation marker. Elevated levels of these
markers have been identified in the serum and urine of
patients with bone metastases. They may provide early indi-
cation of bone metastases and may be elevated even in
patients without radiologic evidence of metastatic bone dis-
ease.84 High-baseline levels of urinary NTX have been shown
to be a strong prognostic indicator of negative outcome in
several cancers including lung cancer, with increased risk of
SREs, disease progression, and death compared with patients
with low-NTX levels.63,85,86 Therefore, measurement of bio-
chemical markers of bone turnover may be useful to monitor
the extent of bone metastases and the overall response to
therapy in the future. An interesting example of this biochem-
ical analysis has been in the targeting of RANK ligand with
denosumab, where osteoclast inhibition correlated with re-
duced urinary NTX levels and a reduction in SREs.73
CONCLUSION
Bone metastases from lung cancer are associated with
considerable negative effects on both patient morbidity and
mortality. Total medical care costs of SREs are significant
among patients with bone metastases from lung cancer.
Zoledronic acid is the first and only bisphosphonate that has
proven efficacy for the treatment of bone metastases from a
broad range of solid tumor types, including lung cancer, and
should be strongly considered for such patients. Future and
ongoing trials will assess the role of bisphosphanates in the
adjuvant setting and assess the efficacy of RANKL antibod-
ies. Use of biomarkers may further identify subgroups of
patients most likely to benefit from bisphosphonates and
perhaps other treatments.
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